Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

ACC/AHA Release New Comprehensive ACS Guidelines

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

February 27, 2025

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Presentation TCT 2024

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Presenter: Hamza Naveed

October 28, 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

October 28, 2024

SCAI Releases Practical, Technical Advice for Primary PCI in STEMI

News Daily News

SCAI Releases Practical, Technical Advice for Primary PCI in STEMI

Michael O'Riordan

October 10, 2024

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

News Daily News

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

April 14, 2023

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

News Daily News

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

October 20, 2022

No Stents in STEMI? With Careful Selection, Maybe

News Daily News

No Stents in STEMI? With Careful Selection, Maybe

March 21, 2022

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

December 22, 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

May 18, 2021

Ticagrelor’s Dominance Over Clopidogrel Again Questioned

News Daily News

Ticagrelor’s Dominance Over Clopidogrel Again Questioned

April 16, 2021

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

News Daily News

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Yael L. Maxwell

April 05, 2021

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

Transradial Access Still Beats Transfemoral for STEMI in Updated Meta-analysis

News Daily News

Transradial Access Still Beats Transfemoral for STEMI in Updated Meta-analysis

November 25, 2020

PCI at Ambulatory Centers: More Bleeding but No Penalty in Overall Outcomes

News Daily News

PCI at Ambulatory Centers: More Bleeding but No Penalty in Overall Outcomes

November 11, 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Large UK Study Explores Use of Excimer Laser Coronary Atherectomy

News Daily News

Large UK Study Explores Use of Excimer Laser Coronary Atherectomy

September 25, 2020

Thrombus Burden Greater in STEMI Patients With COVID-19

News Daily News

Thrombus Burden Greater in STEMI Patients With COVID-19

Michael O'Riordan

July 20, 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.